About Macrocure
Macrocure is a company based in Petah Tikva (Israel) founded in 2008 was acquired by Leap Therapeutics in August 2016.. Macrocure has raised $26 million across 3 funding rounds from investors including Leap Therapeutics, Pontifax Venture Capital and Viola Group. Macrocure operates in a competitive market with competitors including Celgene, Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics and Sonoma Biotherapeutics, among others.
- Headquarter Petah Tikva, Israel
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$26 M (USD)
in 3 rounds
-
Latest Funding Round
$13 M (USD), Series B
Apr 27, 2011
-
Investors
Leap Therapeutics
& 3 more
-
Employee Count
Employee Count
-
Acquired by
Leap Therapeutics
(Aug 29, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Macrocure
Macrocure has successfully raised a total of $26M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $13 million completed in April 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $13.0M
-
First Round
First Round
(01 Mar 2009)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2011 | Amount | Series B - Macrocure | Valuation | Viola Group | |
| Sep, 2009 | Amount | Series A - Macrocure | Valuation |
investors |
|
| Mar, 2009 | Amount | Series A - Macrocure | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Macrocure
Macrocure has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Leap Therapeutics, Pontifax Venture Capital and Viola Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pontifax Venture Capital is focused on life sciences investments.
|
Founded Year | Domain | Location | |
|
Investments are made in early-stage technology companies globally.
|
Founded Year | Domain | Location | |
|
Investments are directed toward Israeli technology startups by Docor.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Macrocure
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Macrocure
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Macrocure Comparisons
Competitors of Macrocure
Macrocure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics and Sonoma Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for cancer and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immune cell therapies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Macrocure
When was Macrocure founded?
Macrocure was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Where is Macrocure located?
Macrocure is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
Who is the current CEO of Macrocure?
Nissim Mashiach is the current CEO of Macrocure.
Is Macrocure a funded company?
Macrocure is a funded company, having raised a total of $26M across 3 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Mar 01, 2009.
What does Macrocure do?
Macrocure was founded in 2008 in Petah Tikva, Israel, within the biotechnology sector. T-cell therapies are developed and commercialized by the company to address wound care needs. The proprietary CureXcell technology is utilized, involving activated white blood cells derived from healthy donor blood to support wound healing processes. Two pivotal Phase III clinical trials are ongoing for lower extremity chronic ulcers and chronic venous leg ulcers.
Who are the top competitors of Macrocure?
Macrocure's top competitors include Juno Therapeutics, Achilles Therapeutics and ArsenalBio.
Who are Macrocure's investors?
Macrocure has 4 investors. Key investors include Leap Therapeutics, Pontifax Venture Capital, Viola Group, and Docor.